Peter Bruce Anderson

8067022, Nov 29, 2011

Jul 20, 2001

09/910388

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

Boston Scientific SciMed, Inc. - Maple Grove MN

A61F 2/00
A61K 31/00

424423, 514 1

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

8097642, Jan 17, 2012

Feb 27, 2007

11/679650

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

A61K 31/40
A61K 31/35

514411, 514455

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

8158670, Apr 17, 2012

Jan 4, 2007

11/650059

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

Boston Scientific Scimed, Inc. - Maple Grove MN

A61K 31/40
A61K 31/35

514411, 514455

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

20090196931, Aug 6, 2009

Apr 3, 2009

12/418209

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

A61K 9/14
A61K 9/00
A61K 31/553
A61K 31/407
A61K 38/18
A61K 31/135
A61K 31/337

424489, 424400, 51421108, 514411, 514 12, 514646, 514449

Methods are provided for inhibiting or treating stenosis or restenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective amount of a therapeutic agent via a catheter. Also provided is a catheter adapted for administering a therapeutically effective amount of a therapeutic agent to a mammalian host for inhibiting or treating stenosis or restenosis.

20110300221, Dec 8, 2011

Aug 15, 2011

13/209956

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

A61K 9/14
A61P 7/00
A61P 9/08
A61K 31/337

424490, 514449

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

20120195951, Aug 2, 2012

Apr 13, 2012

13/446760

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

A61F 2/82

424423

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

58114475, Sep 22, 1998

May 25, 1995

8/450793

Lawrence L. Kunz - Redmond WA
Richard A. Klein - Lynnwood WA
John M. Reno - Brier WA
David J. Grainger - Cambridge, GB2
James C. Metcalfe - Cambridge, GB2
Peter L. Weissberg - Cambridge, GB2
Peter G. Anderson - Birmingham AL

NeoRx Corporation - Seattle WA

A61K 3140

514411

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

60746599, Jun 13, 2000

Jul 10, 1998

9/113733

Lawrence L. Kunz - Redmond WA
Richard A. Klein - Lynnwood WA
John M. Reno - Brier WA
David J. Grainger - Cambridge, GB
James C. Metcalfe - Cambridge, GB
Peter L. Weissberg - Cambridge, GB
Peter G. Anderson - Birmingham AL

NoeRx Corporation - Seattle WA

A61F 200

424423

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.